Skip to content

Efficacy and Safety of a Moisturizing Cream for Sensitive Skin in Improving Skin Sensitivity: A Half-Face, Randomized Controlled Trial

Efficacy and Safety of a Moisturizing Cream for Sensitive Skin in Improving Skin Sensitivity: A Half-Face, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121645
Enrollment
Unknown
Registered
2026-04-01
Start date
2025-05-08
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensitive skin

Interventions

Trial 1 Test Side:Randomly select one half of the face as the test side, and apply the Sensitive Skin Moisturizing Cream 7 on it.Take an appropriate amount of this product and apply it evenly to the t
Trial 1 Test Side:Randomly select one half of the face as the test side, and apply the Sensitive Skin Moisturizing Cream 6 on it.Take an appropriate amount of this product and apply it evenly to the
Trial 1 Control Side:Trial 1: The other side of the face on the experimental side, without using the product.
Trial 1 Control Side:Trial 2: The other side of the face on the experimental side, without using the product.

Sponsors

Dematology Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Healthy females or males aged between 18 and 60 years old. 2.Those who test positive in the lactic acid stinging test. 3.Individuals with sensitive, reddish, and dry facial skin. 4.Those who have good compliance with this project and possess good communication skills. 5.Those who are willing to undergo follow-up and relevant non-invasive tests. 6.Those who can understand the experimental process, voluntarily participate in the experiment, and sign the written informed consent form.

Exclusion criteria

Exclusion criteria: 1.Those who have applied any topical medications to the tested area within the past two months. 2.Those who have taken antihistamines within the past week or immunosuppressants within the past month. 3.Those with inflammatory skin diseases that have not clinically healed. 4.Patients with insulin-dependent diabetes mellitus. 5.Patients with asthma or other chronic respiratory diseases who are currently receiving treatment. 6.Those who have received anti-cancer chemotherapy within the past six months. 7.Patients with immunodeficiency or autoimmune diseases. 8.Women who are planning to become pregnant, are pregnant, or are breastfeeding. 9.Those who have obvious scars, pigmentation, atrophy, nevus flammeus, sunburns, wounds, abrasions, tattoos, or other defects at or near the skin test site, which may affect the determination of the test results. 10.Those who have received medical aesthetic treatments such as intense pulsed light skin rejuvenation, laser treatments, or other facial cosmetic procedures that may affect the skin condition within the past three months. 11.Those who have participated in similar facial tests, oral medication tests, or other clinical trials within the past two months. 12.Those with a high degree of physical sensitivity, and those who are known to be allergic to ingredients in cosmetics or daily chemical products, alcohol, rubber, or medications, etc. 13.Those who need to be exposed to outdoor sunlight for a long time due to work or other reasons. 14.Those with other iatrogenic problems that may affect the test results (such as a history of coagulation disorders, severe hyperglycemia, hypertension, hyperlipidemia, mental diseases, or other major diseases). 15.Those who are considered unsuitable for participating in the trial according to other clinical evaluations. 16.Those who do not volunteer to participate or cannot complete the specified test content as required.

Design outcomes

Primary

MeasureTime frame
Transepidermal water loss;

Secondary

MeasureTime frame
VISIA CR red zone a* value;Lactic Acid Sting Test;Water content of the stratum corneum of the skin;Safety index;

Countries

China

Contacts

Public ContactYe Li

Dematology Hospital of Southern Medical University

dlpfbyy@163.com+86 20 83028375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026